• All
  • Article Title
  • Abstract
  • Keywords
  • Author
  • Institution
  • Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    EiC: Nicola Normanno, Italy
    Frequency: Continuous Publication
    APC: $2,000 per article (See APC Waivers and Discounts)
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: PubMed/PMC, Scopus, Google Scholar, DOAJ, CAS, Dimensions, Portico, etc. The journal is also the member of COPE.
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Review
    An overview of the feasibility of nanomedicine in pancreatic cancer theranostics
    Pancreatic ductal adenocarcinoma (PDAC) is among the top causes of cancer-induced mortality, frequently diagnosed too late to be treated effectively, due to the poor prognosis and the limited succes [...] Read more.
    Kyriakos Kokkinogoulis ... Mersini Makropoulou
    Published: June 18, 2025 Explor Target Antitumor Ther. 2025;6:1002326
    DOI: https://doi.org/10.37349/etat.2025.1002326
    This article belongs to the special issue Use of Different Radiation Treatment Modalities in Cancer Therapy: The Role of Inflammation and Immune Response
    View:15
    Download:3
    Times Cited: 0
    Open Access
    Original Article
    Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
    Aim: BRCA1/2-associated breast and ovarian carcinomas are often regarded as a single entity, assuming that BRCA1 and BRCA2 genes are almost equivalent with regard to their clinical significance [...] Read more.
    Anna Sokolenko ... Evgeny Imyanitov
    Published: June 18, 2025 Explor Target Antitumor Ther. 2025;6:1002325
    DOI: https://doi.org/10.37349/etat.2025.1002325
    View:18
    Download:4
    Times Cited: 0
    Open Access
    Review
    Osteosarcoma: current insights and advances
    Osteosarcoma is the most prevalent primary malignant bone tumor affecting adolescents and young adults. Despite advancements in cancer therapies, its prognosis remains poor due to its aggressive nat [...] Read more.
    Guraustin S. Brar ... Yujiang Fang
    Published: June 15, 2025 Explor Target Antitumor Ther. 2025;6:1002324
    DOI: https://doi.org/10.37349/etat.2025.1002324
    View:112
    Download:11
    Times Cited: 0
    Open Access
    Original Article
    Mutational landscape of epidermoid carcinoma of the penis in a Brazilian cohort
    Aim: Penile cancer (PeCa) is a rare malignancy strongly associated with poor genital hygiene and is more prevalent in regions with low socioeconomic status. PeCa accounts for approximately 2% to  [...] Read more.
    Renato Mendes Rossi De Lucca ... Rodolfo Borges dos Reis
    Published: June 06, 2025 Explor Target Antitumor Ther. 2025;6:1002323
    DOI: https://doi.org/10.37349/etat.2025.1002323
    This article belongs to the special issue Predictive and Prognostic Biomarkers in Cancer: Towards the Precision Medicine Era
    View:301
    Download:9
    Times Cited: 0
    Open Access
    Review
    Role of exosomes in transforming growth factor-β-mediated cancer cell plasticity and drug resistance
    Transforming growth factor-β (TGF-β) is a multifunctional molecule with a dual role in carcinogenesis. Recent studies have demonstrated its various effects on cancer-related processes. However, th [...] Read more.
    Tatiana Ruksha, Nadezhda Palkina
    Published: June 05, 2025 Explor Target Antitumor Ther. 2025;6:1002322
    DOI: https://doi.org/10.37349/etat.2025.1002322
    View:194
    Download:12
    Times Cited: 0
    Open Access
    Review
    Circulating tumor cells: overcoming challenges of detecting a needle in a haystack
    Circulating tumor cells (CTCs) are cancer cells that are detached from the primary and metastatic tumor site and invade the bloodstream. Most importantly, CTCs are the key players in the development [...] Read more.
    Zhuldyz Myrkhiyeva ... Aliya Bekmurzayeva
    Published: May 29, 2025 Explor Target Antitumor Ther. 2025;6:1002321
    DOI: https://doi.org/10.37349/etat.2025.1002321
    This article belongs to the special issue ​Liquid Biopsy: Has Already Changed the Clinical Decision-Making in Solid Tumors Treatment?​​
    View:431
    Download:14
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:34952
    Download:3425
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:22745
    Download:780
    Open Access
    Review
    Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
    Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy  [...] Read more.
    Pierluigi De Santis ... Palma Fedele
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
    DOI: https://doi.org/10.37349/etat.2024.00215
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:10318
    Download:210
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:9364
    Download:209
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:9277
    Download:514
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:9050
    Download:302
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:34952
    Download:3425
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:5065
    Download:1745
    Open Access
    Perspective
    Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
    Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However,  [...] Read more.
    Ai Tsuji ... Satoru Matsuda
    Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:460–473
    DOI: https://doi.org/10.37349/etat.2023.00145
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:3943
    Download:1226
    Open Access
    Perspective
    Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
    Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. M [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: August 24, 2023 Explor Target Antitumor Ther. 2023;4:556–568
    DOI: https://doi.org/10.37349/etat.2023.00152
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:3813
    Download:1127
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:22745
    Download:780
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:9277
    Download:514
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:34952
    Download:3425
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:22745
    Download:780
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:9277
    Download:514
    Open Access
    Review
    Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decisi [...] Read more.
    Vincenza Caputo ... Stefania Napolitano
    Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
    DOI: https://doi.org/10.37349/etat.2023.00125
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    View:5913
    Download:135
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6448
    Download:237
    Open Access
    Review
    Potential role of resveratrol and its nano-formulation as anti-cancer agent
    The uncontrolled and metastatic nature of cancer makes it worse and more unpredictable. Hence, many therapy and medication are used to control and treat cancer. However, apart from this, many medica [...] Read more.
    Akshay Kumar ... Dilpreet Singh
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
    DOI: https://doi.org/10.37349/etat.2022.00105
    This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
    Special Issues